Free Trial
NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

$14.22
-0.12 (-0.84%)
(As of 05/24/2024 ET)
Today's Range
$14.16
$14.90
50-Day Range
$13.65
$25.52
52-Week Range
$4.50
$30.96
Volume
1.07 million shs
Average Volume
750,246 shs
Market Capitalization
$852.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.50

Immunome MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
114.5% Upside
$30.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Immunome in the last 14 days
Based on 16 Articles This Week
Insider Trading
Acquiring Shares
$27,140 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.40) to ($2.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.02 out of 5 stars

Medical Sector

573rd out of 917 stocks

Pharmaceutical Preparations Industry

264th out of 415 stocks

IMNM stock logo

About Immunome Stock (NASDAQ:IMNM)

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

IMNM Stock Price History

IMNM Stock News Headlines

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares
Immunome (NASDAQ:IMNM) Shares Down 4%
Immunome appoints CFO
Immunome (NASDAQ:IMNM) Stock Rating Reaffirmed by Wedbush
Immunome, Inc. Q1 Loss Increases, Misses Estimates
Immunome, Inc. (IMNM)
TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)
See More Headlines
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
5/24/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMNM
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.50
High Stock Price Target
$35.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+114.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-106,810,000.00
Net Margins
-1,829.44%
Pretax Margin
-1,829.44%

Debt

Sales & Book Value

Annual Sales
$14.02 million
Book Value
$4.76 per share

Miscellaneous

Free Float
54,812,000
Market Cap
$852.77 million
Optionable
Optionable
Beta
1.87
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Clay B. Siegall Ph.D. (Age 63)
    President, CEO & Chairman
  • Mr. Max Rosett (Age 34)
    Interim CFO & Executive VP of Operations
  • Mr. Robert Lapetina (Age 49)
    Principal Accounting Officer
  • Mr. Philip Roberts
    Chief Technical Officer
  • Dr. Jack Higgins Ph.D. (Age 44)
    Chief Scientific Officer
  • Ms. Sandra G. Stoneman Esq. (Age 50)
    J.D., Chief Legal Officer, General Counsel & Corporate Secretary
    Comp: $443.43k
  • Mr. Bruce Turner M.D. (Age 60)
    Ph.D., Chief Strategy Officer
  • Dr. Robert J. Lechleider M.D.
    Chief Medical Officer
  • Mr. Kinney Horn (Age 49)
    Chief Business Officer

IMNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunome stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMNM shares.
View IMNM analyst ratings
or view top-rated stocks.

What is Immunome's stock price target for 2024?

6 brokers have issued 12-month price targets for Immunome's shares. Their IMNM share price targets range from $24.00 to $35.00. On average, they expect the company's share price to reach $30.50 in the next twelve months. This suggests a possible upside of 114.5% from the stock's current price.
View analysts price targets for IMNM
or view top-rated stocks among Wall Street analysts.

How have IMNM shares performed in 2024?

Immunome's stock was trading at $10.70 at the beginning of 2024. Since then, IMNM shares have increased by 32.9% and is now trading at $14.22.
View the best growth stocks for 2024 here
.

When is Immunome's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our IMNM earnings forecast
.

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) announced its quarterly earnings data on Thursday, March, 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.26. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative trailing twelve-month return on equity of 37.33% and a negative net margin of 1,829.44%.

What ETF holds Immunome's stock?

Invesco DWA SmallCap Momentum ETF holds 573,596 shares of IMNM stock, representing 0.99% of its portfolio.

When did Immunome IPO?

Immunome (IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

Who are Immunome's major shareholders?

Immunome's stock is owned by many different retail and institutional investors. Top institutional investors include Redmile Group LLC (8.16%), Price T Rowe Associates Inc. MD (3.75%), Vanguard Group Inc. (3.37%), Janus Henderson Group PLC (2.57%), Farallon Capital Management LLC (0.99%) and Lord Abbett & CO. LLC (0.74%). Insiders that own company stock include Bruce Turner, Clay B Siegall, Jean Jacques Bienaime, Michael Lefenfeld, Michael Rapp and Purnanand D Sarma.
View institutional ownership trends
.

How do I buy shares of Immunome?

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMNM) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners